Home › Companies › Jasper Therapeutics, Inc. › 2025-2026
At Jasper Therapeutics, Inc.'s shareholder meeting held July 3, 2025, in the 2025-2026 proxy season, 90 asset managers reported how they voted in their SEC Form N-PX filings, covering 691 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote on approval of the compensation of the named executive officers. — FOR was 94% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Jasper Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on July 3, 2025.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Jasper Therapeutics, Inc.’s Form 8-K, filed July 3, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of July 3, 2025: 5 items on Jasper Therapeutics, Inc.’s Form 8-K, filed July 3, 2025: 5 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Jasper Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Jasper Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed July 3, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Kurt von Emster | 8,467,774 | -- | -- | 186,265 | 3,360,488 | 98% | Not verified | — |
| Elect Director: Scott Brun, M.D. | 8,612,491 | -- | -- | 41,548 | 3,360,488 | 99.5% | Not verified | — |
| Elect Director: Vishal Kapoor | 8,567,506 | -- | -- | 86,533 | 3,360,488 | 99.0% | Not verified | — |
| 2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025 | 11,992,658 | 18,646 | 3,223 | -- | -- | 99.8% | Not verified | — |
| 3. To approve, on an advisory basis, the compensation of the Company's named executive officers | 8,108,299 | 536,022 | 9,718 | -- | 3,360,488 | 94% | Not verified | — |
Source: Jasper Therapeutics, Inc., Form 8-K, filed with the SEC on July 3, 2025 — read the filing on EDGAR.
Each item below shows how the 90 asset managers that disclosed a Jasper Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Jasper Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Class I directors to serve until the 2028 annual meeting of stockholders: Kurt von Emster
Jasper Therapeutics, Inc.’s own tally for this item (“Elect Director: Kurt von Emster”): 8,467,774 for, 186,265 withheld, per its Form 8-K filed July 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 1,362,196 for, 43,002 withheld, 4,606 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 348,969 | 0 | 0 | 0 | For |
| Fidelity | 255,108 | 0 | 0 | 0 | For |
| BlackRock | 240,525 | 0 | 0 | 0 | For |
| T. Rowe Price | 200,206 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 195,441 | 0 | 0 | 0 | For |
| Charles Schwab | 26,648 | 0 | 0 | 0 | For |
| Equitable | 24,830 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 20,215 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 12,837 | Withhold |
| Northern Trust | 10,411 | 0 | 0 | 0 | For |
| TIAA | 9,530 | 0 | 0 | 0 | For |
| AQR | 0 | 0 | 0 | 8,307 | Withhold |
| Lincoln Financial | 8,100 | 0 | 0 | 0 | For |
| Global X | 6,860 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 5,380 | Withhold |
| Goldman Sachs | 0 | 0 | 0 | 5,018 | Withhold |
| Voya | 0 | 0 | 0 | 3,659 | Withhold |
| Nationwide | 3,111 | 0 | 0 | 0 | For |
| Crewe Advisors LLC | 3,100 | 0 | 0 | 0 | For |
| Pacific Life | 2,779 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 2,540 | 0 | Abstain |
| Bridge Builder Trust | 2,199 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 2,076 | Withhold |
| John Hancock | 0 | 0 | 2,066 | 0 | Abstain |
| SEI | 1,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: Election of Class I directors to serve until the 2028 annual meeting of stockholders: Scott Brun, M.D.
Jasper Therapeutics, Inc.’s own tally for this item (“Elect Director: Scott Brun, M.D.”): 8,612,491 for, 41,548 withheld, per its Form 8-K filed July 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 1,392,538 for, 14,726 withheld, 2,540 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 348,969 | 0 | 0 | 0 | For |
| Fidelity | 255,108 | 0 | 0 | 0 | For |
| BlackRock | 240,525 | 0 | 0 | 0 | For |
| T. Rowe Price | 200,206 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 195,441 | 0 | 0 | 0 | For |
| Charles Schwab | 26,648 | 0 | 0 | 0 | For |
| Equitable | 24,830 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 20,215 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 12,837 | Withhold |
| Northern Trust | 10,411 | 0 | 0 | 0 | For |
| TIAA | 9,530 | 0 | 0 | 0 | For |
| AQR | 8,307 | 0 | 0 | 0 | For |
| Lincoln Financial | 8,100 | 0 | 0 | 0 | For |
| Global X | 6,860 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 5,380 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,018 | 0 | 0 | 0 | For |
| Voya | 3,659 | 0 | 0 | 0 | For |
| Nationwide | 3,111 | 0 | 0 | 0 | For |
| Crewe Advisors LLC | 3,100 | 0 | 0 | 0 | For |
| Pacific Life | 2,779 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 2,540 | 0 | Abstain |
| Bridge Builder Trust | 2,199 | 0 | 0 | 0 | For |
| ProShares | 2,076 | 0 | 0 | 0 | For |
| John Hancock | 2,066 | 0 | 0 | 0 | For |
| SEI | 1,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.0% Majority: yes · of votes cast
Description as filed by funds: Election of Class I directors to serve until the 2028 annual meeting of stockholders: Vishal Kapoor
Jasper Therapeutics, Inc.’s own tally for this item (“Elect Director: Vishal Kapoor”): 8,567,506 for, 86,533 withheld, per its Form 8-K filed July 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 1,387,520 for, 19,744 withheld, 2,540 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 348,969 | 0 | 0 | 0 | For |
| Fidelity | 255,108 | 0 | 0 | 0 | For |
| BlackRock | 240,525 | 0 | 0 | 0 | For |
| T. Rowe Price | 200,206 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 195,441 | 0 | 0 | 0 | For |
| Charles Schwab | 26,648 | 0 | 0 | 0 | For |
| Equitable | 24,830 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 20,215 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 12,837 | Withhold |
| Northern Trust | 10,411 | 0 | 0 | 0 | For |
| TIAA | 9,530 | 0 | 0 | 0 | For |
| AQR | 8,307 | 0 | 0 | 0 | For |
| Lincoln Financial | 8,100 | 0 | 0 | 0 | For |
| Global X | 6,860 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 5,380 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 5,018 | Withhold |
| Voya | 3,659 | 0 | 0 | 0 | For |
| Nationwide | 3,111 | 0 | 0 | 0 | For |
| Crewe Advisors LLC | 3,100 | 0 | 0 | 0 | For |
| Pacific Life | 2,779 | 0 | 0 | 0 | For |
| Jackson National | 0 | 0 | 2,540 | 0 | Abstain |
| Bridge Builder Trust | 2,199 | 0 | 0 | 0 | For |
| ProShares | 2,076 | 0 | 0 | 0 | For |
| John Hancock | 2,066 | 0 | 0 | 0 | For |
| SEI | 1,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: Advisory vote on approval of the compensation of the named executive officers.
Jasper Therapeutics, Inc.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers”): 8,108,299 for, 536,022 against, per its Form 8-K filed July 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 348,969 | 0 | 0 | 0 | For |
| Fidelity | 255,108 | 0 | 0 | 0 | For |
| BlackRock | 240,525 | 0 | 0 | 0 | For |
| T. Rowe Price | 200,206 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 195,441 | 0 | 0 | 0 | For |
| Charles Schwab | 26,648 | 0 | 0 | 0 | For |
| Equitable | 24,830 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 20,215 | 0 | 0 | 0 | For |
| Dimensional | 0 | 12,837 | 0 | 0 | Against |
| Northern Trust | 10,411 | 0 | 0 | 0 | For |
| TIAA | 9,530 | 0 | 0 | 0 | For |
| AQR | 8,307 | 0 | 0 | 0 | For |
| Lincoln Financial | 8,100 | 0 | 0 | 0 | For |
| Global X | 6,860 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 5,380 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,018 | 0 | 0 | 0 | For |
| Voya | 3,659 | 0 | 0 | 0 | For |
| Nationwide | 3,111 | 0 | 0 | 0 | For |
| Pacific Life | 2,779 | 0 | 0 | 0 | For |
| Jackson National | 0 | 2,540 | 0 | 0 | Against |
| Bridge Builder Trust | 2,199 | 0 | 0 | 0 | For |
| ProShares | 2,076 | 0 | 0 | 0 | For |
| John Hancock | 2,066 | 0 | 0 | 0 | For |
| SEI | 1,900 | 0 | 0 | 0 | For |
| DWS | 1,788 | 0 | 0 | 0 | For |
Fund voting reports, all 35 managers: 1,389,438 for, 17,266 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 1,433,828 | 0 | 0 | 0 | For |
| Soleus Capital Management, L.P. | 1,121,431 | 0 | 0 | 0 | For |
| Carlyle Group Inc. | 1,066,189 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 545,171 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 534,713 | 0 | 0 | 0 | For |
| T. Rowe Price | 474,516 | 0 | 0 | 0 | For |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 440,000 | 0 | 0 | 0 | For |
| Integral Health Asset Management, LLC | 379,639 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 273,534 | 0 | 0 | 0 | For |
| BlackRock | 243,801 | 203 | 0 | 0 | For |
| State Street | 123,301 | 32 | 0 | 0 | For |
| Northern Trust | 57,136 | 0 | 0 | 0 | For |
| Rhumbline | 18,028 | 0 | 0 | 0 | For |
| Nuveen | 28,381 | 0 | 0 | 0 | For |
| Goldman Sachs | 27,444 | 0 | 0 | 0 | For |
| Charles Schwab | 26,648 | 0 | 0 | 0 | For |
| Vanguard | 23,071 | 0 | 0 | 0 | For |
| STATE OF WISCONSIN INVESTMENT BOARD | 22,487 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 20,891 | 0 | 0 | 0 | For |
| Citadel | 19,882 | 0 | 0 | 0 | For |
| Fidelity | 18,559 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 18,198 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 12,839 | 0 | 0 | 0 | For |
| AQR | 8,461 | 0 | 0 | 0 | For |
| Cumberland Partners Ltd | 6,250 | 0 | 0 | 0 | For |
Institutional-manager reports, all 72 managers: 6,991,906 for, 17,224 against, 80 not voted, 18,028 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
100% Fund and manager reports combined; may count the same shares twice · no official result
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| Dimensional | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| AQR | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 0 | 0 | 0 | 0 | -- |
| Global X | 0 | 0 | 0 | 0 | -- |
| AIG/SunAmerica | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| Voya | 0 | 0 | 0 | 0 | -- |
| Nationwide | 0 | 0 | 0 | 0 | -- |
| Pacific Life | 0 | 0 | 0 | 0 | -- |
| Jackson National | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| ProShares | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
| SEI | 0 | 0 | 0 | 0 | -- |
| DWS | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 35 managers: 1,390,547 1 year, 16,157 3 year. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Velan Capital Investment Management LP | 0 | 0 | 0 | 0 | -- |
| Soleus Capital Management, L.P. | 0 | 0 | 0 | 0 | -- |
| Carlyle Group Inc. | 0 | 0 | 0 | 0 | -- |
| Rock Springs Capital Management LP | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 0 | 0 | 0 | 0 | -- |
| Integral Health Asset Management, LLC | 379,639 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| Rhumbline | 18,028 | 0 | 0 | 0 | For |
| Nuveen | 0 | 0 | 0 | 0 | -- |
| Goldman Sachs | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| STATE OF WISCONSIN INVESTMENT BOARD | 0 | 0 | 0 | 0 | -- |
| MELLON INVESTMENTS Corp | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 0 | 0 | 0 | -- |
| STIFEL NICOLAUS & CO INC \MO\ | 0 | 0 | 0 | 0 | -- |
| AQR | 0 | 0 | 0 | 0 | -- |
| Cumberland Partners Ltd | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 71 managers: 397,667 for, 80 not voted, 5,186,502 1 year, 1,433,828 unknown, 3,845 3 year. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Majority: yes · of votes cast
Description as filed by funds: Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
Jasper Therapeutics, Inc.’s own tally for this item (“2. To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025”): 11,992,658 for, 18,646 against, per its Form 8-K filed July 3, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 36 asset managers below reported 1,409,804 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 348,969 | 0 | 0 | 0 | For |
| Fidelity | 255,108 | 0 | 0 | 0 | For |
| BlackRock | 240,525 | 0 | 0 | 0 | For |
| T. Rowe Price | 200,206 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 195,441 | 0 | 0 | 0 | For |
| Charles Schwab | 26,648 | 0 | 0 | 0 | For |
| Equitable | 24,830 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 20,215 | 0 | 0 | 0 | For |
| Dimensional | 12,837 | 0 | 0 | 0 | For |
| Northern Trust | 10,411 | 0 | 0 | 0 | For |
| TIAA | 9,530 | 0 | 0 | 0 | For |
| AQR | 8,307 | 0 | 0 | 0 | For |
| Lincoln Financial | 8,100 | 0 | 0 | 0 | For |
| Global X | 6,860 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 5,380 | 0 | 0 | 0 | For |
| Goldman Sachs | 5,018 | 0 | 0 | 0 | For |
| Voya | 3,659 | 0 | 0 | 0 | For |
| Nationwide | 3,111 | 0 | 0 | 0 | For |
| Crewe Advisors LLC | 3,100 | 0 | 0 | 0 | For |
| Pacific Life | 2,779 | 0 | 0 | 0 | For |
| Jackson National | 2,540 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 2,199 | 0 | 0 | 0 | For |
| ProShares | 2,076 | 0 | 0 | 0 | For |
| John Hancock | 2,066 | 0 | 0 | 0 | For |
| SEI | 1,900 | 0 | 0 | 0 | For |
Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 15,022,122 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 2.32% |
| 2 | Fidelity | 1.70% |
| 3 | BlackRock | 1.60% |
| 4 | T. Rowe Price | 1.33% |
| 5 | FRANKLIN STRATEGIC SERIES | 1.30% |
| 6 | Charles Schwab | 0.18% |
| 7 | Equitable | 0.17% |
| 8 | QUANTITATIVE MASTER SERIES LLC | 0.13% |
| 9 | Dimensional | 0.09% |
| 10 | Northern Trust | 0.07% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Velan Capital Investment Management LP | 9.54% |
| 2 | Soleus Capital Management, L.P. | 7.47% |
| 3 | Carlyle Group Inc. | 7.10% |
| 4 | Rock Springs Capital Management LP | 3.63% |
| 5 | FRANKLIN ADVISERS INC | 3.56% |
| 6 | T. Rowe Price | 3.16% |
| 7 | KINGDON CAPITAL MANAGEMENT, L.L.C. | 2.93% |
| 8 | Integral Health Asset Management, LLC | 2.53% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.82% |
| 10 | BlackRock | 1.62% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Velan Capital Investment Management LP | — | 13G |
| Velan Capital Management LLC and Affiliates | — | DEF14A |
| MCN HOLDCO LLC | — | DEF14A |
| BANK OF AMERICA CORP /DE/ | — | 13G |
| Morgan Stanley | — | 13F |
| Millennium Management | — | 13F |
| Anders Hove | — | 13G |
| Vanguard Group | — | 13F |
| The Carlyle Group Inc. | — | 13D |
| Patrick Crutcher | — | DEF14A |
Percentages above are of 15,022,122 shares outstanding, as reported by Jasper Therapeutics, Inc. on its Form 10-Q dated May 8, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Jasper Therapeutics, Inc.’s 10-Q dated May 8, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Jasper Therapeutics, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Jasper Therapeutics (JSPR) 2025 Annual Meeting (2025-2026 season)”, https://proxyvotesnow.com/company/jasper-therapeutics-inc/2026 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.